Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability (2022 - 2025)

Ascentage Pharma Group International (AAPG) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $1.8 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 141.78% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (up 141.78% YoY), and the FY2025 full-year result was $1.8 million, up 149.39% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $1.8 million, up from $747310.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.5 million in Q4 2022 and bottomed at $747310.0 in Q4 2024.
• The 4-year median for Non-Current Deferred Tax Liability is $2.0 million (2025), against an average of $1.8 million.
• The widest annual swing landed in 2024, when Non-Current Deferred Tax Liability tumbled 66.29%; it then surged 141.78% in 2025.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $2.5 million in 2022, then retreated by 9.79% to $2.2 million in 2023, then slumped by 66.29% to $747310.0 in 2024, then soared by 141.78% to $1.8 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $1.8 million (Q4 2025), $747310.0 (Q4 2024), and $2.2 million (Q4 2023), per Business Quant data.

Peer Comparison